Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHATHOM PHARMACEUTICALS INC.
PHAT | US
15.52
USD-0.56
-3.48%
PHAT | US
About PHATHOM PHARMACEUTICALS INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
15.52
Open
16.15
High
16.27
Low
15.42
Phathom Pharmaceuticals Inc. biopharmaceutical company focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States Europe and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals Inc. was incorporated in 2018 and is headquartered in Florham Park New Jersey.
View LessPHAT | US
Risk
53.0
Sharpe
0.80
Luna's Score
43/100
Recommendation
Sell
Luna says (PHAT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
56.3%1 month
53.0%3 months
61.5%6 months
61.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
25.37
Debt to equity
-2.17
Debt to assets
1.59
Ent. to EBITDA
-2.20
Ent. to rev.
101.64
PEG
-
Other Fundamentals
EBITDA
-252.07M
MarketCap
1.06B
MarketCap(USD)
1.06B
Div. yield
-
Op. margin
-1.06K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-3.49K
Short ratio
15.37
Short perc.
35.61
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.37
Range1M
4.17
Range3M
9.25
Volumes: Market Activity
Rel. volume
1.41
Price X volume
20.10M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.20 | - | Cheaper |
| Ent. to Revenue | 101.64 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 25.37 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 61.50 | - | Par |
| Debt to Equity | -2.17 | -1.23 | Cheaper |
| Debt to Assets | 1.59 | 0.25 | Expensive |
| Market Cap | 1.06B | - | Emerging |
